The story
Dove Medical Press is a privately held company founded in 2003 by Tim Hill, a former managing director of Adis International and five other founders.
As of 11 April 2013, 42 of the 131 journals were indexed in PubMed, while 30 of the 131 journals had fewer than ten articles.
In 2013, the Dove Medical Press journal Drug Design, Development and Therapy accepted a false and intentionally flawed paper created and submitted by an investigative journalist for Science as part of a "sting" to test the effectiveness of the peer-review processes of open access journals (Who's Afraid of Peer Review?). The Open Access Scholarly Publishers Association terminated Dove's membership as a result of the incident. After satisfying The Open Access Scholarly Publishers Association Membership Committee that new editorial and peer review procedures were in place to address the concerns raised during its investigation, Dove Medical Press was reinstated as a full member of Open Access Scholarly Publishers Association in September 2015.
In September 2017, Dove Medical Press was acquired by the Taylor & Francis Group.
In 2022, a study re-analyzing the predatory publishers on Beall's list found that Dove Medical Press was among the "most reputable" of 18 publishers previously labelled as predatory, which could have marked a "transition into a reputable, open-access journal".
From Wikipedia’s article on Dove Medical Press, shared under CC BY-SA 4.0.5